drugset / Trial / NCT07531628

A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants

NCT07531628

Phase 1 Active not recruiting 9 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

To assess pharmacokinetics, safety, and tolerability of multiple oral doses of verducatib in healthy Chinese male and female trial participants in order to facilitate the clinical development of verducatib in China.

Timeline

Start
2026-06-10
Primary completion
2026-08-10
Completion
2026-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1291583 Unknown Oral

Indications

No indication recorded.